Novel targets in aggressive lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33275737/
Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after...
-
Mark Fesler4yrThis article is a very nice overview of the many different routes by which dlbcl can be attacked
-
Mark Fesler4yrIt appears that, like with CarT, COO is not prognostic in the context of autoSCT
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33274677/
Anti-CD19 chimeric antigen receptor (CAR) T cells represent the first approved third-line therapy associated with long-term remissions in patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). Eligibility criteria to...
-
Mark Fesler4yrNot a full article access link so further detail would help but authors are trying to convey that CAR T is not a widely applicable therapy
-
Mark Fesler4yrRchop superiority over chop has been known for about 25 years
Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
Source : https://link.springer.com/article/10.1007/s00277-020-04341-7
High-dose methotrexate (HD-MTX) at 3 g/m2 is one of the strategies for central nervous system (CNS) prophylaxis in the first-line treatment of aggressive lymphomas, especially in diffuse large B cell...
-
Mark Fesler4yrInteresting outpatient strategy with a regimen most would only administer inpatient. It would be helpful if additional studies expand this work with a comparison of AEs and discontinuation rates Show More